Skip to main content

3 FREE Biotech/Healthcare Research Reports: Atossa Genetics Inc. (ATOS), Johnson & Johnson, Inc. (JNJ), & Pfizer Inc. (PFE)

SAN FRANCISCO, CA / ACCESSWIRE / January 23, 2018 / All three reports are available for FREE at the Vista Partners Coverage Page.

Seattle based Atossa Genetics Inc. (NASDAQ: ATOS) is a clinical-stage drug company developing novel, proprietary therapeutics and delivery methods for breast cancer and other breast conditions. They believe their innovative therapies and delivery methods can transform breast cancer treatment. DOWNLOAD the complete FREE Report at http://www.vistapglobal.com/vp-coverage/atossa-genetics-inc-atos/.

Dow 30 component Johnson & Johnson, Inc. (JNJ) is an investment holding company with interests in healthcare products. It engages in research and development, manufacture and sale of personal care hygienic products, pharmaceuticals and surgical equipment. DOWNLOAD the complete FREE Report at http://www.vistapglobal.com/vp-coverage/johnson-johnson/.

Dow 30 component Pfizer, Inc. (PFE) discovers, develops, manufactures, and sells healthcare products worldwide. DOWNLOAD the complete FREE Report at http://www.vistapglobal.com/vp-coverage/pfizer-2/.

Vista Partners offers a wealth of mixed-media resources on the Dow 30 & Select Emerging Growth Companies. Visit www.vistapglobal.com/signup to stay informed with FREE email updates.

About VISTA PARTNERS

Founded in 2005, Vista Partners LLC (''Vista'') is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista's proprietary equity and market research to help you stay informed and stay competitive. Vista's mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

We encourage readers to view a complete list of disclaimers and disclosures on the Vista Partners website at VistaPGlobal.com/disclaimer.

Please follow Vista Partners on Twitter @VistaPResearch to receive updates, thoughts, and ideas on Dow 30 Components, Select Emerging Growth Companies & Vista's Featured Companies.

SOURCE: Vista Partners LLC

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.